Ken Griffin
SPRY icon

Ken Griffin’s ARS Pharmaceuticals SPRY Stock Holding History

Ken Griffin’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$418K Buy
52,000
+35,200
+210% +$337K ﹤0.01% 9735
2025
Q4 		$196K Buy
16,800
+2,000
+14% +$19.4K ﹤0.01% 11065
2025
Q3 		$149K Sell
14,800
-3,300
-18% -$47.4K ﹤0.01% 11537
2025
Q2 		$316K Sell
18,100
-10,800
-37% -$156K ﹤0.01% 9697
2025
Q1 		$364K Buy
28,900
+17,200
+147% +$207K ﹤0.01% 9159
2024
Q4 		$123K Buy
11,700
+9,100
+350% +$127K ﹤0.01% 11143
2024
Q3 		$37.7K Sell
2,600
-17,500
-87% -$208K ﹤0.01% 12208
2024
Q2 		$171K Sell
20,100
-5,100
-20% -$45.3K ﹤0.01% 10155
2024
Q1 		$258K Sell
25,200
-6,800
-21% -$50.7K ﹤0.01% 9797
2023
Q4 		$175K Sell
32,000
-17,100
-35% -$74.9K ﹤0.01% 10140
2023
Q3 		$186K Buy
49,100
+9,100
+23% +$59.7K ﹤0.01% 10039
2023
Q2 		$268K Buy
40,000
+2,400
+6% +$16K ﹤0.01% 9286
2023
Q1 		$245K Sell
37,600
-2,000
-5% -$15.4K ﹤0.01% 9800
2022
Q4 		$338K Buy
39,600
+27,400
+225% +$178K ﹤0.01% 9062
2022
Q3 		$64K Sell
12,200
-49,100
-80% -$242K ﹤0.01% 11451
2022
Q2 		$260K Buy
+61,300
New +$214K ﹤0.01% 10137

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Ken Griffin's SPRY Position: Q1 2026 in Review

Ken Griffin reduced its ARS Pharmaceuticals (SPRY) stake by 9.3% in Q1 2026, selling an estimated $1.74M and leaving 1,773,188 shares worth $14.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2753.

Ken Griffin first reported a position in SPRY in Q4 2020 and has held it in 21 quarters since. The position peaked at $39.1M in Q2 2025. 203 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Ken Griffin held 1,773,188 shares of ARS Pharmaceuticals worth $14.2M as of Q1 2026.
  • Ken Griffin sold 181,284 ARS Pharmaceuticals shares in Q1 2026, an estimated $1.74M.
  • ARS Pharmaceuticals made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #2753 holding.
  • Ken Griffin first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 21 quarters since.
  • Ken Griffin's ARS Pharmaceuticals position peaked at $39.1M in Q2 2025.
  • 203 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.